• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Eloxx Pharmaceuticals, Inc.

    6/14/21 4:01:32 PM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELOX alert in real time by email
    SC 13G 1 tm2119668d1_sc13g.htm SCHEDULE 13G
     

     

    CUSIP No. 29014R103 SCHEDULE 13G Page    1    of    7   

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    SCHEDULE 13G

     

     

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

     

    Eloxx Pharmaceuticals, Inc.

     

    (Name of Issuer)

     

     

    Common Stock, par value, $0.01 per share

     

    (Title of Class of Securities)

     

     

    29014R103

     

    (CUSIP Number)

     

     

    April 1, 2021

     

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨  Rule 13d-1(b)

     

    x  Rule 13d-1(c)

     

    ¨  Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 29014R103 SCHEDULE 13G Page    2    of    7   

     

    1.

    NAMES OF REPORTING PERSONS

    Roche Finance Ltd

       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨
      (b) ¨
       
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Switzerland

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

     

    5. SOLE VOTING POWER 0
       
       
    6.

    SHARED VOTING POWER

    2,532,270

     

       
    7.

    SOLE DISPOSITIVE POWER

    0

     

       
    8.

    SHARED DISPOSITIVE POWER

    2,532,270

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,532,270

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)

    EXCLUDES CERTAIN SHARES (See Instructions)

    ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.3%

    12.

    TYPE OF REPORTING PERSON (See Instructions)

     

    CO

     

     

     

     

    CUSIP No. 29014R103 SCHEDULE 13G Page    3    of    7   

     

    1.

    NAMES OF REPORTING PERSONS

    Roche Holding Ltd

       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨
      (b) ¨
       
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Switzerland

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

     

    5. SOLE VOTING POWER 0
       
       
    6.

    SHARED VOTING POWER

    2,532,270

     

       
    7.

    SOLE DISPOSITIVE POWER

    0

     

       
    8.

    SHARED DISPOSITIVE POWER

    2,532,270

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,532,270

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)

    EXCLUDES CERTAIN SHARES (See Instructions)

    ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.3%

    12.

    TYPE OF REPORTING PERSON (See Instructions)

     

    CO

     

     

     

     

    CUSIP No. 29014R103 SCHEDULE 13G Page    4    of    7   

     

    Item 1(a).Name of Issuer:

     

    Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    950 Winter Street, Waltham, Massachusetts 02451

     

    Item 2. 

     

    (a) Name of Person Filing: Roche Finance Ltd and Roche Holding Ltd

     

    (b) Address or principal business office or, if none, residence:

     

    Roche Finance Ltd: Grenzacherstrasse 122, 4070 Basel, Switzerland.

     

    Roche Holding Ltd: Grenzacherstrasse 124, 4070 Basel, Switzerland.

     

    (c) Citizenship:

     

    Roche Finance Ltd: Switzerland

     

    Roche Holding Ltd: Switzerland

     

    (d) Title of Class of Securities: Common Stock, par value, $0.01 per share.

     

    (e) CUSIP No.: 29014R103.

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership:

     

    (a)Each of the Reporting Persons may be deemed to beneficially own 2,532,270 shares of Common Stock.*

     

    (b)Percent of Class: Each Reporting Person may be deemed to beneficially own 5.3%, based on 47,856,257 shares of Common Stock outstanding as of May 3, 2021 as reported in the Issuer’s Quarterly Report on Form 10-Q for the period ended March 31, 2021.*

     

    (c)Number of shares as to which each Reporting Person has:

     

    (i)       Sole power to vote or to direct the vote: 0.

     

    (ii)       Shared power to vote or to direct the vote: 2,532,270.

     

    (iii)       Sole power to dispose or to direct the disposition of: 0.

     

    (iv)       Shared power to dispose or to direct the disposition of: 2,532,270.

     

    *Roche Holding Ltd may be deemed to have beneficial ownership of the 2,532,270 shares directly beneficially owned by Roche Finance Ltd, its wholly-owned subsidiary.

     

     

     

     

    CUSIP No. 29014R103 SCHEDULE 13G Page    5    of    7   

     

    Item 5.Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following     ¨.

     

    Not applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person:

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    Roche Finance Ltd is a wholly-owned subsidiary of Roche Holding Ltd.

     

    Item 8.Identification and Classification of Members of the Group:

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group:

     

    Not applicable.

     

    Item 10.Certification:

     

    Not applicable.

     

     

     

     

    CUSIP No. 29014R103 SCHEDULE 13G Page    6    of    7   

     

    SIGNATURE

     

    After reasonable inquiry and to the best of their knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated this 14th day of June, 2021

     

      ROCHE FINANCE LTD  
           
           
      By: /s/ Carole Nuechterlein  
      Carole Nuechterlein, Authorized Signatory  
           
           
      By: /s/ Beat Kraehenmann  
      Beat Kraehenmann, Authorized Signatory  
           
           
           
           
      ROCHE HOLDING LTD  
           
           
      By: /s/ Beat Kraehenmann  
      Beat Kraehenmann, Authorized Signatory  
           
           
      By: /s/ Claudia Boeckstiegel  
      Claudia Boeckstiegel, Authorized Signatory  

      

     

     

     

    CUSIP No. 29014R103 SCHEDULE 13G Page    7    of    7   

     

    JOINT FILING AGREEMENT

     

    The undersigned hereby agree to jointly prepare and file with regulatory authorities this Schedule 13G and any future amendments thereto reporting each of the undersigned’s ownership of securities of the Issuer named herein, and hereby affirm that such Schedule 13G is being filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that he or it knows or has reason to believe that such information is inaccurate. It is understood and agreed that the joint filing of the Schedule 13G shall not be construed as an admission that the persons named herein constitute a group for purposes of Regulation 13D-G of the Exchange Act, nor is a joint venture for purposes of the Investment Company Act of 1940.

     

    Dated this 14th day of June, 2021

     

      ROCHE FINANCE LTD  
           
           
      By: /s/ Carole Nuechterlein  
      Carole Nuechterlein, Authorized Signatory  
           
           
      By: /s/ Beat Kraehenmann  
      Beat Kraehenmann, Authorized Signatory  
           
           
           
           
      ROCHE HOLDING LTD  
           
           
      By: /s/ Beat Kraehenmann  
      Beat Kraehenmann, Authorized Signatory  
           
           
      By: /s/ Claudia Boeckstiegel  
      Claudia Boeckstiegel, Authorized Signatory  

      

     

    Get the next $ELOX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELOX

    DatePrice TargetRatingAnalyst
    12/17/2021$4.00Outperform
    Oppenheimer
    11/18/2021$2.00 → $1.00Neutral
    HC Wainwright & Co.
    11/11/2021$3.00 → $2.00Neutral
    HC Wainwright & Co.
    6/30/2021$3.10Buy
    Mizuho
    More analyst ratings

    $ELOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Eloxx Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Eloxx Pharmaceuticals with a rating of Outperform and set a new price target of $4.00

      12/17/21 5:45:41 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Eloxx Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $1.00 from $2.00 previously

      11/18/21 6:16:16 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Eloxx Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $2.00 from $3.00 previously

      11/11/21 6:39:05 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Walts Alan Edmund was granted 12,000 shares, increasing direct ownership by 1,274% to 12,942 units (SEC Form 4)

      4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

      10/17/24 4:02:21 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Androski Lindsay was granted 12,000 shares (SEC Form 4)

      4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

      10/17/24 4:01:56 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Rubin Steven D was granted 12,000 shares (SEC Form 4)

      4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

      10/17/24 4:01:36 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Leadership Updates

    Live Leadership Updates

    See more
    • Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer

      Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017630946/en/Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire) Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage oncology comp

      10/17/23 8:00:00 AM ET
      $ATAI
      $ATOS
      $ELOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer

      SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces the appointment of Greg Weaver as the Company's new Chief Financial Officer (CFO). Mr. Weaver succeeds Kyle Guse. A short video interview with Mr. Weaver about his background and vision for Atossa can be found here: https://youtu.be/G6ZzHLh-qsQ Mr. Weaver brings more than 30 years of life sciences, financial and operations experience to the Company. Recently, he served as CFO of privately held BioIntelliSense, a commerc

      6/1/23 9:10:00 AM ET
      $ATAI
      $ATOS
      $ELOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Eloxx Pharmaceuticals Announces Changes to Board of Directors

      Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra step down from the Eloxx board WATERTOWN, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the appointment of Lindsay Androski, JD, MBA to its board of directors and as a member of the Board's Audit Committee and Compensation Committee. Current board members Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr.

      7/5/22 8:00:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Financials

    Live finance-specific insights

    See more
    • Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

      Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class 1 CF ELX-02 was well tolerated with no drug-related serious adverse events observed Evidence of activity for ELX-02 observed; efficacy signal potentially confounded by variability due to low drug exposure Path forward for ELX-02 for the treatment of Class 1 CF to be determined together with CF Foundation Company to host conference call and webcast today, September 14, 2022, at 4:30 p.m. ET WATERTOWN, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare d

      9/14/22 4:05:00 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

      ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity ELX-02 monotherapy results support advancement of ELX-02 into Phase 3 clinical development First patient dosed in Phase 2 ELX-02 expansion treatment arms evaluating combination with ivacaftor; topline data expected by the end of the first half of 2022 Company to host conference call and webcast Wednesday, November 17, 2021 at 8:30 am ET WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare dise

      11/17/21 7:00:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Acquires Zikani Therapeutics

      Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms Maximizes Potential for ELX-02 for Cystic Fibrosis in Phase 2 Development Adds Preclinical Stage Pipeline in Rare Diseases and Oncology Targeting RNA and Ribosomal Mutations Expects to File IND for First Oral Drug to Treat Patients with Recessive Dystrophic and Junctional Epidermolysis Bullosa (RDEB and JEB) Sumit Aggarwal, Zikani President and CEO, to Lead the Combined Company Eloxx to Issue Approximately 7.6 Million Shares to Zikani Stockholders Company to Host Investor Call at 8:30 a.m. ET, April 1 WALTHAM, Mass. and WATERTOWN, Mass., April 01, 2021 (GLOBE NEWSWIRE

      4/1/21 7:45:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Eloxx Pharmaceuticals Inc.

      SC 13D/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

      8/20/24 8:13:16 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Eloxx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

      2/13/23 4:52:16 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Eloxx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

      2/14/22 6:18:22 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    SEC Filings

    See more
    • SEC Form NT 10-Q filed by Eloxx Pharmaceuticals Inc.

      NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

      11/19/24 4:01:28 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

      10/17/24 4:01:29 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form NT 10-Q filed by Eloxx Pharmaceuticals Inc.

      NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

      8/14/24 4:01:27 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

      Data from Eloxx's proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm production of both collagen alpha 4 and collagen alpha 5 in patients post treatment with ELX-02 Results justify the need to conduct a larger clinical trial of ELX-02 in NMAS to confirm clinical benefit U.S. Food and Drug Administration (FDA) allows for continued dosing of subjects in Phase 1 trial of ZKN-013 WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases w

      11/12/24 4:05:00 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

      First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations Positive written FDA feedback and guidance from a pre-Investigational New Drug Application (PIND) meeting provides pathway to IND application submission to initiate a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS) Secured binding commitment for additional $3.2 million financing to advance our clinical programs WATERTOWN, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted gene

      7/11/24 11:46:35 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

      ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Global Licensing Partnership for ZKN-013 with Almirall Pharmaceuticals with $3M upfront and up to $470M in milestones and Tiered Royalties on Global Sales New Paper Published on Autosomal Dominant Polycystic Kidney Disease (ADPKD) shows that ELX-02 treatment prevents cyst formation in diseased PKD organoids with nonsense mutations and a single healthy gene copy WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWI

      4/16/24 7:30:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care